Skip to main content
. 2016 Jan 21;21:773–782. doi: 10.1007/s10147-016-0952-6

Table 3.

Primary reasons for discontinuation

Category and reason Phase I (N = 9) Phase II (N = 38)
Discontinuation in multiple-dose period (early termination), n (%)
 Adverse event 0 5 (13.2)
 Worsening of disease 1 (11.1) 5 (13.2)
 Withdrawal by subject 0 2 (5.3)
Discontinuation in overall study, n (%)
 Adverse event 0 8 (21.1)
 Worsening of disease 5 (55.6) 18 (47.4)
 Withdrawal by subject 0 2 (5.3)